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cultured rat mesangial cells demonstrated a significant increaseDiabetes mellitus increases endothelin-1 gene transcription in
in immunofluorescence labeling of ET-1 peptide and ET-1rat kidney.
mRNA in response to increasing concentrations of glucose. Fur-Background. Mesangial cell hypertrophy and increased ex-
thermore, transfected mesangial cells exposed to 22.5 mmol/Ltracellular matrix (ECM) contribute to mesangial expansion
d-glucose showed a 1.6-fold increase in ET-1 promoter activityin early progressive diabetic nephropathy. Previous studies sug-
gest that the growth factor endothelin-1 (ET-1) is not only up- relative to those treated with 5.6 mmol/L glucose.
regulated in diabetes, but may mediate the effects of hypergly- Conclusion. Glucose increases ET-1 gene expression in the
cemia on mesangial cell hypertrophy and ECM synthesis. In kidney of the SZT-treated rat model of diabetes mellitus. Fur-
models of diabetes mellitus, the mechanisms underlying in- thermore, high glucose induces ET-1 expression in primary
creased ET-1 peptide and mRNA remain unknown. Therefore, cultured rat mesangial cells and directly enhances ET-1 pro-
our purpose is to determine whether ET-1 gene activity in- moter activity. The greater relative increase in peptide com-
creases in kidneys of streptozotocin (SZT)-treated rats. pared with transcription suggests the potential participation of
Methods. Male Sprague-Dawley rats were injected with either other mechanisms such as increased mRNA stability, protein
SZT or vehicle. Parameters including glucose, body weight, stability, and/or enhanced translational efficiency.
24-hour urine volume, urinary protein, and urinary ET-1
excretion were recorded. All rats were sacrificed at 12 weeks
postinjection. Prepro-ET-1 mRNA from whole kidneys was
Endothelin-1 (ET-1) is a 21-amino acid peptide thatdetermined using both RNase protection and reverse transcrip-
tion-polymerase chain reaction (RT-PCR). The abundance of has a wide range of biologic activities that includes being
ET-1 peptide in primary cultured mesangial cells was detected one of the most potent vasoconstrictors known to date.
by indirect immunofluorescence following treatment with 5.6, ET-1 was initially isolated from the conditioned media
11.2, or 22.5 mmol/L d-glucose for 24 hours. Cellular ET-1
of porcine aortic endothelial cells [1]. The current reportmRNA was measured using RT-PCR in control cells at time
focuses on the potential role of ET-1 in the pathogenesis0 and also following exposure to increasing concentrations of
glucose for 24 hours. Rat mesangial cells were transfected with of diabetic nephropathy. This complication is one of the
a luciferase reporter construct containing the rat ET-1 pro- most dreaded consequences of diabetes mellitus (DM)
moter (pET1.Luc), and relative ET-1 promoter activity was because of its association with high mortality [2]. The
measured after a 24-hour exposure to 5.6 and 22.5 mmol/L of
results of these studies are expected to provide newd- or l-glucose.
knowledge that will help us to understand better theResults. After 12 weeks of hyperglycemia, diabetic rats gained
less weight (344 6 23.9 vs. 548.75 6 15.08 g), had increased uri- etiology of this complication.
nary volume (158.6 6 24.32 vs. 8.38 6 1.56 mL/day), and had Several lines of evidence point to the participation of
marked proteinuria (101.7 6 12.2 vs. 14.1 6 2.8 mg/day) com- ET-1 in the pathogenesis of diabetic nephropathy. Forpared with controls. Total urinary ET-1 peptide increased 26.4-
example, extracellular matrix (ECM) expansion is one offold in diabetic versus control rats (17.5083 6 5.405 vs. 0.6635 6
the dominant histologic abnormalities found in diabetic0.343 ng/day). ET-1 mRNA extracted from whole rat kidneys
was increased 2.1-fold in diabetic versus control animals. Primary nephropathy. The results of recent studies support the
idea that ET-1 peptide may trigger increased production
of several protein components of ECM [3]. The possibil-
Key words: progressive diabetic nephropathy, mesangial cells, glucose,
ity that ET-1 underlies the histologic changes in the kid-vasoconstriction, extracellular matrix, amino acid peptide, hypergly-
cemia. ney of diabetic nephropathy is further strengthened by
the fact that glomerular ET-1 mRNA is increased five-
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haps ET-1 acts in an autocrine fashion and stimulates Each animal was assessed at four-week intervals for
the cells that express this peptide to undergo changes total body weight, tail vein glucose, and 24-hour urinary
associated with diabetic nephropathy. Another line of volume. Aliquots of urine were stored at 2708C for total
evidence supporting the involvement of ET-1 comes protein and ET-1 peptide determinations. The collection
from the use of an ET-1 receptor antagonist in diabetic of a 24-hour urine sample was carried out by placing each
animals. The administration of these antagonists to the animal in a metabolic cage. Total urinary protein was
diabetic animals blocks the expected increases in glomer- measured using the Bradford assay (Bio-Rad, Hercules,
ular mRNA that encode growth factors and selected CA, USA), and bovine serum albumin was used to gener-
ECM proteins. Members of this group of drugs also ate the standard curve. Each sample was assayed in tripli-
reduce urinary protein excretion [5, 6]. In other studies, cate. Urinary ET-1 peptide concentration was measured
angiotensin-converting enzyme (ACE) inhibitors, a class using a specific radioimmunoassay kit containing a rabbit
of drugs well known to halt the progression of early polyclonal primary antibody against ET-1 (#RIK-6901;
diabetic nephropathy and decrease glomerular ET-1 Peninsula Labs, Belmont, CA, USA). The polyclonal
gene expression in diabetic rats, were used [7]. Together, antisera in this kit cross-reacted with various ET iso-
these findings point to a potentially important role of forms: ET-1, 100%; ET-2, 7%; and proET-1, 17%. ET-1
ET-1 in the pathogenesis of diabetic nephropathy. peptide was first extracted from the urine samples using
Despite previous studies showing enhanced expression pretreated C18 Sep-columns (#RIK-SEPCOL1; Penin-
of the ET-1 gene in the setting of hyperglycemia, the sula Labs) according to the manufacturer’s instructions,
molecular mechanism(s) underlying the increase remains and was lyophilized and stored at 2708C. The lyophilized
unknown. The purpose of the current study is to deter- samples were resuspended in the recommended buffer
mine whether increased ET-1 expression in glomeruli solution, and the ET-1 concentration was determined
exposed to high concentrations of glucose arises from using the radioimmunoassay technique. Total daily uri-
changes in gene activity. We postulate that hyperglyce- nary ET-1 peptide excretion was calculated by multi-
mia enhances transcriptional activity of the ET-1 gene, plying the ET-1 concentration and the total 24-hour
which leads to increased glomerular levels of ET-1 urine volume.
mRNA and protein in the SZT-treated rat model of DM. All rats were sacrificed 12 weeks after SZT injection.
In the present study, we examined the changes in ET-1 The kidneys were dissected from these animals, and
urinary peptide and renal prepro-ET-1 mRNA after 12 100 mg were snap frozen using liquid nitrogen and stored
weeks of hyperglycemia in the SZT-treated rat model at 2708C for the extraction of RNA at a later date.
of diabetes. The actions of glucose were extended to
primary cultured mesangial cells. These findings support Primary culture of rat glomerular mesangial cells
the idea that glucose has a direct effect on activity of
Mesangial cells were obtained from glomeruli of 200 gthe ET-1 gene.
male Sprague-Dawley rats as previously described [8].
Glomeruli were isolated by progressive sieving of chopped
METHODS renal cortex using 250, 106, and finally 75 mm stainless
steel sieves (Newark Wire Cloth Co., Newark, NJ, USA).Animal studies
The isolated glomeruli were cultured in Dulbecco’sMale Sprague-Dawley rats weighing 200 to 225 g were
modified Eagle’s medium (DMEM; GIBCO BRL, Lifepurchased from the University of Calgary (Campus
Technologies, Mississauga, Ontario, Canada) containingBreeders, Calgary, Alberta, Canada) and housed under
5.6 mmol/L d-glucose, l-glutamine, and 110 mg/L sodiumstandard temperature and lighting conditions. The ani-
pyruvate, supplemented with sodium bicarbonate (3.7 g/L),mals were allowed free access to water and fed with
HEPES (2.38 g/L), 1% penicillin-streptomycin (GIBCOregular rat chow (Purina, St. Louis, MO, USA). DM was
BRL), and 20% fetal bovine serum (FBS; GIBCO BRL).induced in the rats by an intraperitoneal injection of 100
Primary mesangial cells were identified by positive im-mg/kg body wt SZT (Upjohn, Kalamazoo, MI, USA)
munofluorescence for the intermediate filaments desmindissolved in sterile water. Control animals were given
and vimentin but were negative for cytokeratin. Mesan-intraperitoneal injections of the same volume of vehicle
gial cells from passages 13 to 17 were used for all experi-alone. Twenty-four hours following injection, the glucose
ments and were cultured to 90% confluence in six-welllevel in the rats was measured using a Medisense gluco-
(35 mm) plates coated with 50 mg/mL human plasma fibro-meter (Abbott Laboratories, Montreal, Quebec, Can-
nectin (Becton Dickinson, Mississauga, Ontario, Canada).ada) with blood obtained by tail vein puncture. If the
For cells exposed to high glucose, an appropriate volumeblood glucose was less than 13 mmol/L, the rats were
of a 1 mol/L solution of either d- or l-glucose was addedgiven a second intraperitoneal injection of the same dose
to serum-poor media (0.5% FBS) to yield a final concen-of SZT. None of the control or diabetic animals were
treated with insulin. tration of 22.5 mmol/L.
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Immunofluorescence labeling of ET-1 in cultured the antisense primer specific for rat prepro-ET-1 cDNA
spanning nucleotides 717 to 740 (59-ACTTTGCAAmesangial cells
CTCGAAAGGAGGTCT-39) and Superscript II RTCells were grown in DMEM supplemented with 20%
(GIBCO BRL) in a final volume of 20 mL. A 2 mL ali-FBS overnight prior to labeling. Primary cultured rat mes-
quot of this product was used for the PCR reaction. A 554angial cells were grown on fibronectin-coated glass cover
bp product was amplified using Taq polymerase (948Cslips and were then treated with DMEM (0.5% FBS)
denaturation, 588C annealing, 728C extension, 30 cycles;containing 5.6, 11.2, or 22.5 mmol/L glucose for 24 hours.
Pharmacia, Uppsala, Sweden) and 10 pmol of specificThe cells were fixed and permeabilized with a solution
primers for ET-1 (sense, ATGGATTATTTTCCCGTcontaining a mixture of 3.7% formaldehyde, 0.25%
GATCTTC; antisense, ACTTTGCAACTCGAAAGGglutaraldehyde, and 0.25% Triton-X in PEM buffer
AGG-TCT), corresponding to sequences spanning 186[160 mmol/L PIPES, 10 mmol/L egtazic acid (EGTA),
to 208 and 717 to 740, respectively, of the rat prepro-4 mmol/L MgCl2, pH 6.9] for 10 minutes at room temper-
ET-1 cDNA. For the b-actin control, 5 mg of total RNAature. After washing three times with phosphate-buf-
were reverse transcribed as described previously in thisfered saline (PBS), the cells were treated with the reduc-
article using 2 pmol of a specific antisense primer (TAAing agent sodium borohydride, 1 mg/mL in PBS [9] for five
CAGTCCGCCTAGAAGCATTTGCG). The same de-minutes. The cells were washed again and then blocked
naturing, annealing, and extension conditions used forwith 1% goat serum for 10 minutes at room temperature.
the ET-1 PCR were used for the b-actin PCR. To 2 mLRabbit polyclonal anti–ET-1 antibody (Peninsula Labs)
of the first strand reaction, the same antisense primerwas diluted 1:200 with PBS and added to each cover slip
used for the RT reaction and the sense primer (CATand incubated in a humid chamber for 60 minutes at
GAAGTGTGACGTTGACATCC) were added for 30room temperature. After washing, the FITC-conjugated
cycles. The reverse transcription-polymerase chain reac-secondary antibody (goat antirabbit IgG, H1L; Jackson
tion (RT-PCR) protocol for cultured mesangial cells dif-ImmunoResearch Labs, West Grove, PA, USA) diluted
fered slightly in that 2 mg of total RNA and 1.25 mL1:200 in PBS was added for 45 minutes at room tempera-
(0.5 mg/mL) of oligodT (GIBCO BRL) were used insteadture. Cells were washed and mounted on glass slides
of 5 mg total RNA and the specific ET-1 antisense primerusing mounting media containing 0.1% P-phenylene di-
used for tissue samples. The PCR products were run onamine and 50% glycerol in PBS. The FITC-labeled ET-1
a 1% agarose gel and stained with ethidium bromide. Thepeptide in cells was visualized using a Zeiss fluorescence
relative band intensity was analyzed using quantitativemicroscope (Zeiss, Dusseldorf, Germany) with FITC ex-
scanning densitometry. The value for each ET-1 mRNAcitation and emission wavelengths of 488 and 520 nm,
sample was standardized relative to the amount ofrespectively. Photographs were taken using Kodak Elite
b-actin mRNA signal obtained following 30 cycles ofChrome 100 film (Eastman Kodak Co., Rochester, NY,
PCR for the same sample. RNase protection analysis wasUSA). Exposure times of one minute were performed
performed with 10 mg of total RNA from mesangial cellsfor all slides. Final magnification was 3250. Each experi-
using the RiboQuant kit (PharMingen, San Diego, CA,ment was performed in triplicate.
USA) according to the manufacturer’s instructions. The
Preparation of RNA radiolabeled cRNA probe was synthesized by inserting
the 554 bp ET-1 cDNA described previously in this arti-Total RNA was extracted from rat kidneys and pri-
cle into pGEM-T and then digesting this construct withmary cultured mesangial cells using TRIZOL Reagent
Xmn I. The 2239 bp fragment when transcribed with(GIBCO BRL, Burlington, Ontario, Canada). The yield
RNA polymerase Sp6 (Pharmacia) in the presence ofof total RNA was determined by measuring optical den-
a-[32P]-UTP (800 Ci/mmol) yielded radiolabeled cRNAsity at 260 nm, and purity was assessed by the ratio of
probe used in the RNase protection assay. Each reactionoptical densities at 260 and 280 nm (average ratio 1.7).
contained 106 cpm of radiolabeled cRNA. Autoradio-For cell culture experiments, mesangial cells were grown
grams were analyzed using quantitative scanning densi-in DMEM supplemented with 20% FBS overnight; 16 to
tometry or a phosphoimager (Molecular Dynamics, Pis-24 hours later, the media were changed to serum-poor
cataway, NJ, USA).DMEM (0.5% FBS) with d- or l-glucose added according
to the glucose concentrations. The cells were exposed
DNA constructsto 5.6 or 22.5 mmol/L of either d- or l-glucose in 0.5%
To clone the rat ET-1 promoter, we synthesized twoFBS for 24 hours, and then cells were used for RNA
oligonucleotide primers that flank the DNA fragmentextraction.
spanning 2594 to 157 of the gene (sense, GTTTAAA
RT-PCR and RNase protection measurement of AAAGACTTGGGGG; antisense, TGCAGGACAAG
prepro-ET-1 mRNA CGGAGC-AGA). These primers were used in a PCR
reaction (948C denaturing, 588C annealing, 728C exten-Total RNA (5 mg) extracted from kidneys of control
and diabetic rats was reverse transcribed using 2 pmol of sion, 30 cycles) with rat genomic DNA as the template.
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Fig. 1. DM increases urinary levels of ET-1. (A) The rise in blood glucose and urinary volumes in diabetic rats compared with controls over a
time period of three months. Additionally, total body weight declined in the diabetic rats compared with controls. (B) The rise in total urinary
protein and ET-1 peptide in the same animals. Each value reflects the mean 6 SD. **P , 0.01, according to analysis of variance of data.
The 651 bp product was purified, cloned into the using the CAT assay as described previously [11]. The
20% FBS-supplemented DMEM was aspirated frompGEM-T (Promega, Madison, WI, USA) vector, and
then sequenced using the standard dideoxy technique. the cells; 1 mL of media was added to the DNA-
SUPERFECT mixture before being applied to the cells.Results demonstrated that it was identical to the rat
ET-1 promoter from nucleotides 2594 to 157 [10]. The The cells were incubated with the complexes for two
hours at 378C and 5% CO2. The complex-containingresulting construct, pGEMT-ETP, was then used as the
template for a subsequent PCR reaction using primers media were then aspirated. Cells were washed once with
PBS, and fresh serum-poor (0.5% FBS) DMEM wascontaining a Sac I restriction enzyme site at the 59 end
and Sac I and Kpn I sites at the 39 end (sense, GGAGCT added to each well. Transfected cells were allowed to
recover overnight and were then exposed to either nor-CGTTTAAAAAAGACTTGG; antisense, GGAGCTC
GGTACCGCAGGACAAGCGGG). The 662 bp prod- mal (5.6 mmol/L) or high-glucose (22.5 mmol/L) condi-
tions for 24 hours. Cells were harvested and suspendeduct was purified, cloned into pGEMT again, and cut with
Sac I, and this purified fragment was then cloned into in CCLR lysis buffer (Promega). A 20 mL aliquot of this
lysate was used for determination of luciferase activity,the luciferase reporter plasmid vector pGL3 (Promega)
at the Sac I site. Colonies were screened for the resulting and 10 mL were used for total protein determination
(Bradford assay, Bio-Rad reagent). The luciferase activityET-1 promoter-containing plasmid (pET1.Luc, 5482 bp)
in the forward orientation by assessing products of re- from each measurement was expressed relative to the
protein concentration of that sample. The relative ET-1striction enzyme digestion with Kpn I and Xba I.
promoter activity was calculated by dividing the lucifer-
Transient transfection and luciferase assay ase activity per mg protein by CAT activity (% conver-
sion/mg protein/hour) in the same cells.Mesangial cells were subcultured in DMEM supple-
mented with 20% FBS and seeded onto fibronectin-
Statistical analysiscoated, six-well (35 mm) plates at 24 hours prior to trans-
fection; 1.5 to 2.0 3 105 cells were seeded per well, such Final densitometric ratio data, as well as relative lucif-
erase activity, were expressed as mean 6 SD. Statisticalthat the cells would be 50 to 60% confluent at the time
of transfection. One and a half micrograms of pET1. significance was determined using analysis of variance.
P , 0.05 was accepted as statistically significant.Luc and 0.5 mg of pSV2-CAT in 100 mL of DMEM
free of serum and antibiotics were mixed with 5 mL
of SUPERFECT Transfection Reagent (Qiagen, Inc.,
RESULTS
Mississauga, Ontario, Canada). The solution was incu-
Weight, blood glucose, and urine volume inbated for 10 minutes at room temperature. A plasmid,
diabetic ratspSV2-CAT, contains the bacterial reporter gene CAT
driven by the SV40 promoter. Cellular uptake of this After 12 weeks of hyperglycemia, the diabetic rats
gained less weight than the control animals (344 6 23.9plasmid enabled us to monitor transfection efficiency
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Fig. 2. DM increases renal ET-1 mRNA. (A) An ethidium bromide stained gels of RT-PCR products that reflect ET-1 mRNA abundance in total
kidney RNA from a diabetic (upper) and control (lower) rat. The intensity of the bands was plotted as a function of cycle number and shows a
linear rise in the product between 26 and 32 cycles of PCR. (B) The relative abundance of ET-1 mRNA in total kidney RNA from controls (4)
and diabetic (10) rats. Each value reflects the mean 6 SD. Analysis of variance showed a significant difference between the diabetic and control
rats with P , 0.05.
vs. 548.75 6 15.08 g), as demonstrated in Figure 1A. The cation. Product amplification demonstrated that the use
of 30 cycles for determining yield falls within the linearmean blood glucose values in the diabetic animals were
28.8, 23.7, and 18.9 mmol/L at 4, 8, and 12 weeks postin- range of the reaction. The relative abundance of prepro-
ET-1 mRNA was 1.8-fold higher in the kidneys of dia-jection of SZT, respectively. As expected, the diabetic
rats also demonstrated a significant increase in urinary betic compared with that in control rats (Fig. 2B).
volume (158.6 6 24.32 vs. 8.38 6 1.56 mL/day for con-
High glucose increases ET-1 peptide in culturedtrols; Fig. 1A).
mesangial cells
Diabetes mellitus increases urinary protein and Representative immunofluorescence images of ET-1
ET-1 peptide staining in mesangial cells treated with 5.6, 11.2, and 22.5
mmol/L d-glucose are illustrated in Figure 3A. Immuno-Figure 1B illustrates the incremental increase in 24-
hour urinary total protein and ET-1 peptide excretion fluorescence labeling was uniform throughout the cyto-
plasm. The intensity appeared to increase as the concen-after 4, 8, and 12 weeks of hyperglycemia. Diabetic ani-
mals developed marked proteinuria (101.7 6 12.2 vs. tration of glucose rose. Next, the abundance of ET-1
mRNA in the cultured cells was measured using RT-14.13 6 2.79 mg/day at 12 weeks), and total urinary
ET-1 peptide was increased by 26.4-fold (0.6635 6 0.343 PCR following exposure to glucose concentrations of
5.6, 11.2, and 22.5 mmol/L. The results in Figure 3Bvs. 17.508 6 5.405 ng/day at 12 weeks) compared with
controls. and C showed that levels of the mRNA rose following
exposure to increasing concentrations of glucose. In con-
Diabetes mellitus increases renal prepro-ET-1 mRNA trast, b-actin mRNA levels in the cells did not change
regardless of the glucose concentration.The results of the RT-PCR experiments using RNA
extracted from the kidney of control and diabetic rats
High glucose increases prepro-endothelin-1 mRNA inare illustrated in Figure 2. Representative photographs
cultured mesangial cellsof the ethidium bromide-stained agarose gels are shown.
Figure 2A shows the ET-1 signal of RT-PCRs products Mesangial cells were grown in DMEM with 20% FBS
overnight, then exposed to serum-poor media (0.5%)from a diabetic (top panel) and control (lower panel)
rat kidneys following 26, 28, 30, and 32 cycles of amplifi- containing 5.6 mmol/L d-glucose, 22.5 mmol/L d- or
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Fig. 3. Glucose increases ET-1 expression in primary cultured mesangial cells. (A) The increased ET-1 peptide, as detected by immunoflorescence,
in primary cultured mesangial cells correlates with rising concentrations of glucose (5.6, 11.2, and 22.5 mmol/L) in the media. (B) Ethidium bromide-
stained agarose gels containing products of RT-PCR that reflect the abundance of ET-1 and b-actin mRNA in primary cultured mesangial cells
exposed to 5.6, 11.2, and 22.5 mmol/L glucose. (C ) A graph showing the increase in ER-1 mRNA as a function of rising concentrations of glucose
in the media. Each value reflects the mean 6 SD. *P , 0.05; **P , 0.01, as determined by analysis of variance.
l-glucose (osmotic control), and harvested at 0 and 24 cells remained the same regardless of d-, l- or concentra-
tion of glucose used to treat the cells.hours following exposure. The RNA extracted from
these cells was used as template in RT-PCR to measure Since RT-PCR is semiquantitative, we used the RNase
protection assay to measure ET-1 mRNA levels in mes-the abundance of prepro-ET-1 and b-actin mRNA (Fig.
4A). At time 0, there was no difference in the abundance angial cells exposed to 22.5 and 5.6 mmol/L glucose (Fig.
4C). The ET-1 cRNA probe is comprised of two bandsof prepro-ET-1 mRNA from cells exposed to 22.5 and
5.6 mmol/L d-glucose. However, following 24 hours of (Fig. 4C, lane 1). The nonspecific hybridization of this
probe to 10 mg of yeast tRNA was not significant. Consis-treatment with 5.6 mmol/L d-glucose, the levels of pre-
pro-ET-1 mRNA decreased compared with that in cells tent with the results of RT-PCR, total RNA from cells
exposed to 24 hours of 22.5 mmol/L glucose protectedat time 0. In contrast, there was a 2.1-fold increase in
prepro-ET-1 mRNA levels in cells treated with 22.5 radiolabeled ET-1 cRNA 1.8-fold more than in the 5.6
mmol/L-treated cells. The slightly higher fold increasemmol/L d-glucose relative to those exposed to 5.6
mmol/L glucose (Fig. 4B). The expression of prepro- of ET-1 mRNA between RT-PCR and RNase protection
likely arises from differences in the techniques used.ET-1 mRNA was not affected by 24 hours of treatment
with 22.5 mmol/L l-glucose compared with the level in Together, these studies using two different assays of ET-1
mRNA show that abundance of this sequence increasescells exposed to 5.6 mmol/L d-glucose at time 0. The
levels of b-actin mRNA (Fig. 4A, lower panels) in the following exposure to high levels of glucose.
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Fig. 4. Glucose increases ET-1 mRNA in mesangial cells. (A) RT-PCR products that reflect the levels of ET-1 mRNA from primary culture
mesangial cells exposed to 5.6 or 22.5 mmol/L d-/l-glucose at 0 time, lanes 1 through 3. Lanes 4 through 6 show changes in the level of ET-1
mRNA following 24 hours of exposure to varying concentrations and isoforms of glucose. The RT-PCR product of b-actin mRNA appears below
the ET-1 photographs, and the concentration of glucose is noted at the bottom of each lane. (B) The relative levels of ET-1 mRNA in primary
culture mesangial cells exposed to 5.6 or 22.5 mmol/L d-/l-glucose for 24 hours. Each bar reflects the mean 6 SD of at least three separate
experiments. (C ) An autoradiograph of results using RNase protection. Lane 1, probe alone; lanes 2 and 3, abundance of ET-1 cRNA protected
in 10 mg of total mRNA from mesangial cells treated with 5.6 mmol/L glucose for 24 hours; lanes 4 and 5, abundance of ET-1 cRNA protected
in 10 mg of total mRNA from mesangial cells treated with 22.5 mmol/L glucose for 24 hours.
Rat ET-1 promoter is responsive to high glucose efficiency of transfection was the same among separate
studies. ET-1 promoter activity increased 1.6-fold in cellsFigure 5A shows a schematic map of a plasmid that
treated with 22.5 mmol/L compared with that in cellscontains the rat ET-1 promoter fused to the luciferase
exposed to 5.6 mmol/L d-glucose (Fig. 5D). Promotergene. The products from digesting pET1.Luc with the
activity was not significantly different between cellsrestriction enzymes Kpn I and Xba I yielded fragments
treated with 22.5 mmol/L l-glucose compared with thosewith sizes of 3076, 1742, 452, and 212 bp (Fig. 5B) and
in 5.6 mmol/L d-glucose.verified that the ET-1 promoter was inserted into the
reporter construct in the forward orientation. Mesangial
cells were transfected with pET1.Luc and exposed to 5.6
DISCUSSIONd-glucose or 22.5 mmol/L d- or l-glucose for 24 hours.
Diabetic nephropathy is one of the most serious conse-Cotransfection of the pSV2-CAT (Fig. 5C) construct
followed by assaying for CAT activity showed that the quences of DM. The need for further insight into the
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Fig. 5. Activity of ET-1 promoter is enhanced by glucose. (A) A schematic map showing the site of several restriction enzymes in pET1.Luc, a
plasmid that contains the rat ET-1 promoter fused to the reporter gene luciferase. (B) An ethidium bromide stained agarose gel of fragments
arising from the digestion of the pET1.Luc with Kpn I and Xba I. (C ) Autoradiographs (left) and a graph (right) of CAT-activity from three
separate cotransfections of cells with pSV2-CAT and pET1.Luc for each group of treatment with 5.6 or 22.5 mmol/L glucose. Each bar shows the
mean 6 SD of at least four separate experiments. (D) A graph showing increased relative ET-1 promoter activity (calculated as described in the
Methods section) in primary cultured mesangial cells transfected with pET1.Luc followed by treatment with 5.6 or 22.5 mmol/L d-glucose. Each
bar shows the mean 6 SD of at least four separate experiments.
mechanism(s) underlying this disease provides the ratio- genesis of diabetic nephropathy, we measured the abun-
dance of the peptide in urine (Fig. 1B) from the diabeticnale for the current studies. To investigate the potential
role of ET-1 in the pathogenesis of diabetic nephropathy, animals and noted a 26-fold increase relative to that
in euglycemic controls. Since ET-1 is a small peptidewe used an accepted model of DM derived from rats
injected with SZT. Consistent with the expected changes (molecular weight of 2492), increased filtration of ET-1
may account, in part, for the higher levels of the peptideobserved in rats with DM, the diabetic animals had
higher blood glucose levels and urinary volumes but in urine. In addition, some increase may be due to a
reduced uptake of filtered ET-1 by the proximal tubules,lower total body weight compared with euglycemic con-
trols (Fig. 1A). The finding of proteinuria (.100 mg/ but the 26-fold rise in urine content is unlikely explained
by this mechanism alone. We postulate that the increaseday; Fig. 2) in the diabetic rats indicates the presence of
glomerular dysfunction in these animals. Therefore, this could arise from enhanced activity of the gene in glomer-
ular or tubular cells. Therefore, we measured prepro-model appears appropriate for our studies.
To investigate the potential role of ET-1 in the patho- ET-1 mRNA (Fig. 2) in whole kidney. The mRNA was
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1.8-fold higher in the diabetic rats relative to that in the port for this idea comes from the studies of enalapril,
an ACE inhibitor that slows the progression of diabeticcontrols. This finding is consistent with the results of
Fukui et al, who demonstrated, using Northern blot anal- nephropathy. This drug significantly reduces the levels
of renal ET-1 mRNA in diabetic rats. Despite the factysis, a 3.8-fold increase of the mRNA encoding ET-1 in
SZT-treated rats after 12 weeks of hyperglycemia. An that enalapril had no effect on increased glomerular
mRNA levels for growth factors such as tumor necrosiseven greater increase in ET-1 mRNA was evident after
24 weeks of hyperglycemia [4]. Additionally, Benigni factor-a (TNF-a), TGF-b, platelet-derived growth fac-
tor-B (PDGF-B), and basic fibroblast growth factoret al have previously shown a twofold rise of ET-1 tran-
scripts in diabetic versus control animals [6]. The same (bFGF), the reduction in glomerular ET-1 mRNA corre-
lated with amelioration of proteinuria in the diabeticinvestigators used in situ hybridization to show that the
rise in ET-1 mRNA was due in part to enhanced gene animals [7]. On the other hand, treatment of diabetic
rats with an endothelin receptor antagonist significantlyactivity in the distal tubule epithelial cells of diabetic
rats. Furthermore, glomerular staining for ET-1 was not attenuated the increase in glomerular mRNA levels for
ECM components, including a1(I), a1(III), and a1(IV)detected in controls, but a significant increase was ob-
served in the kidneys of diabetic rats. collagen chains, and laminin B1 and B2 chains. In addi-
tion, the expected increase in glomerular mRNA levelsThe preceding results fit well with clinical data showing
that patients with both type 1 and type 2 DM have in- for TNF-a, PDGF-B, TGF-b, and bFGF arising from
DM was attenuated by the ET-1 antagonist [5]. Together,creased urinary excretion of ET-1 [12, 13]. In these pa-
tients, the magnitude of the rise in urinary ET-1 corre- these findings show that ET-1 is a key factor in the
disease.lates well with the severity of nephropathy, as manifested
by albuminuria [14]. Plasma levels of ET-1 have also First, we tested whether ET-1 gene expression is en-
hanced in mesangial cells exposed to high glucose, be-been reported to be elevated in humans with DM [15, 16].
Although we measured ET-1 levels in the plasma from cause alteration in the phenotype is a cardinal feature
of diabetic nephropathy. Accordingly, we examined theboth diabetic and control rats, a significant difference
between the two groups was not detected (data not effect of varying concentrations of glucose on ET-1 ex-
pression in primary cultured mesangial cells (Fig. 3). Theshown). The difference between humans and rats may
relate to species specificity or sensitivity of the assay in relative expression of ET-1 peptide was measured using
indirect immunofluorescence labeling of the peptide.detecting ET-1 levels.
Although the preceding results are consistent with Mesangial cells exposed to varying concentrations of glu-
cose were labeled for ET-1 using a specific antibody.published reports showing increased levels of ET-1 pep-
tide and mRNA in the kidneys of diabetic animals, this Results showed that the intensity of fluorescence varied
directly with the concentration of glucose in the cultureinformation provides no further insight into the mecha-
nism of the complication. One possible mechanism un- media. The most intense signal was noted in cells exposed
to the highest concentration of glucose. Next, we usedderlying the increase in ET-1 peptide and mRNA in DM
is by enhancing transcription of the gene. To investigate RT-PCR to measure the abundance of ET-1 mRNA
(Figs. 3 and 4) in primary cultured cells exposed to 5.6,this possibility, we focused the following studies on the
mesangial cells because ET-1 expression in these cells is 11.2, and 22.5 mmol/L glucose. Cells treated with the
higher concentrations of glucose for 24 hours had morebelieved to act in an autocrine fashion to enhance ECM
production leading to diabetic nephropathy [3, 17]. ET-1 mRNA compared with those exposed to 5.6 mmol/L
glucose. The increased abundance of ET-1 mRNA follow-We chose to use primary cultured mesangial cells to
study the regulation of ET-1 expression in response to ing exposure to 22.5 mmol/L glucose agrees with results
of the RNase protection assay (Fig. 4C). The results ofone of the pathognomonic features of DM—high glu-
cose—because these cells are believed to play a major these studies showed two important points. First, the
mesangial cell is one of the sites in the kidney whererole in the pathogenesis of diabetic nephropathy. High
glucose has been shown to stimulate the production of ET-1 is induced by glucose. Second, both ET-1 peptide
and mRNA in these cells are enhanced following treat-ECM in mesangial cells directly [18]. Furthermore, these
cells constitutively produce ET-1 [19], and secretion of ment with 11.2 and 22.5 mmol/L glucose compared with
that in the control cells.the peptide from mesangial cells is stimulated by factors
such as angiotensin II [20] and transforming growth fac- The preceding observations prompted us to measure
ET-1 promoter activity in the mesangial cells. A con-tor-b (TGF-b) [19]. Both of these growth factors are up-
regulated in the setting of DM [21–24]. One hypothesis struct containing 662 bp of the ET-1 promoter fused to
Luc was created and then used as a reporter to assayis that ET-1 may act as the focal point for integrating
the actions of factors such as TGF-b and angiotensin II the activity of the gene in mesangial cells. Results showed
that 22.5 mmol/L glucose increased the amount of Luc[25, 26]. Thus ET-1 is believed to play a central role in
the pathogenesis of diabetic nephropathy. Added sup- activity by 1.6-fold after 24 hours (Fig. 5). This observa-
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tion shows clearly that glucose has a direct effect on crine fashion to trigger intracellular signaling. Perhaps
activity of the promoter. The activity of the promoter the increased cellular ET-1 expression has an amplifica-
in the transfected mesangial cells fits closely with ET-1 tion effect on itself, or adjacent cells, to cause further
mRNA levels in the kidneys of diabetic animals, noted stimulation of ET-1. Although we have not examined
previously in this article. the pathways by which glucose stimulates ET-1 promoter
The ET-1 promoter was cloned and characterized in activity, agents that induce ET-1 expression such as
1995 by Paul et al [10]. Sequence analysis identified puta- PDGF, vasopressin, and thrombin have been studied.
tive binding sites for several transcription factors that They act via receptors coupled to the phospholipase
could be involved in regulating rat ET-1 gene expression. C-mediated signaling system. Furthermore, mesangial
One of the most notable was an activator protein-1 (AP-1; cells with low intrinsic protein kinase C (PKC) activity
c-fos/c-jun) binding site that spanned nucleotides 2102 or blocked by H-7, a PKC inhibitor, do not increase
to 2109 of the gene. Interestingly, a recent report sug- ET-1 expression in response to stimulation by phorbol
gests that hyperglycemia induced the binding activity of ester or serum [31]. Substantial evidence supports a role
AP-1 in human mesangial cells [27]. An earlier investiga- for PKC contributing to the glucose-induced early signal-
tion by Kawana et al revealed that the transcription ing events that cause increased ECM accumulation by
factors GATA-2 and AP-1 were not only necessary for cultured mesangial cells [32, 33]. Amplification of the
activity of the ET-1 gene, but interacted synergistically ET-1 response in mesangial cells may involve the activa-
to regulate its transcription [28]. Therefore, it is possible tion of mitogen-activated protein kinase (MAPK), and
that the stimulatory effects of high glucose on ET-1 tran- this response is PKC dependent [34]. Together, these
scription may require the participation of AP-1, GATA-2, observations suggest an important role for PKC in the
or both factors. Paul et al also found that angiotensin II
actions of ET-1. This may cause other perturbations such
had a dose-dependent stimulatory effect on ET-1 pro-
as ECM production [3], which is a hallmark of diabeticmoter activity in transfected bovine aortic endothelial
nephropathy.cells [10]. They did not test the effect of high glucose on
The fact that we found a greater relative increase inET-1 promoter activity, and we plan to investigate whether
ET-1 peptide (26-fold) compared with the mRNA andthere are synergistic effects of high glucose and angiotensin
transcription rate in the animal studies suggests thatII on ET-1 promoter activity in future experiments.
other mechanisms such as increased mRNA stability,Previous studies by others that investigate ET-1 ex-
enhanced mRNA stability, increased translational effi-pression in response to DM have examined either the
ciency, and/or protein stability could play a role in DM-peptide or mRNA, but not both. To our knowledge, the
induced increased expression of ET-1. Bitzan et al havecurrent report is the first to provide a complete study
shown that increased mRNA stability plays a significantof renal ET-1 peptide and its corresponding mRNA.
role in increased ET-1 expression in their model systemFurthermore, the study of these parameters plus tran-
of thrombotic microangiopathy [35].scription of the gene was extended to mesangial cells
In summary, ET-1 gene expression is increased in thebecause we suspected the importance of this cell type in
SZT-treated rat model of diabetes and also in primarythe pathogenesis of diabetic nephropathy. Thus, ET-1
cultured rat mesangial cells exposed to high glucose. Wegene expression was measured in primary cultured mes-
have demonstrated that glucose increases activity of theangial cells by immunofluorescence labeling of the pep-
ET-1 promoter in rat mesangial cells. Further studiestide. RT-PCR was used to measure the levels of ET-1
are required to elucidate the molecular mechanism(s)mRNA, and activity of the ET-1 promoter activity was
by which high glucose stimulates ET-1 promoter activity.determined by transient transfection, in response to vary-
ing concentrations of glucose. Yamauchi et al demon- These topics will be the focus of future studies, which
strated that 22.5 mmol/L glucose significantly increased will give us further insight into the role of ET-1 in the
secretion of ET-1 from cultured bovine aortic endothe- pathogenesis of diabetic nephropathy.
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